IHH Healthcare bets on clinical longevity to counter Asia's aging and lifestyle disease burden

IHH Healthcare, Asia's largest private health group, is introducing a preventive health program called Healthspan to combat rising lifestyle diseases and aging populations. The initiative emphasizes clinical interventions such as resistance training and GLP-1 drugs to prevent age-related conditions, rather than cosmetic wellness. The company is also expanding ambulatory care centers in dense cities to offer community-based treatments without hospital admissions.

IHH's origins trace to 2010, when Malaysian sovereign fund Khazanah Nasional consolidated its healthcare holdings into a single entity. The company went public in 2012 through a dual listing in Singapore and Malaysia, raising $2 billion in what ranked as that year's third-largest IPO globally. Growth has largely come through acquisitions, including India's Globe Healthcare in 2015.

The group now operates 89 hospitals across ten markets with roughly $6 billion in annual revenue. Healthspan currently runs only in Singapore, though leadership intends to extend it to other territories including India, Turkey, and Greater China. The company is simultaneously building smaller community-based facilities in dense urban centers to complement its hospital network.